Associations - CDKN2A deletion

CDKN2A deletion CDKN2A deletion	B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Mantle Cell Lymphoma Mantle Cell Lymphoma	ibrutinib Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Acute Lymphocytic Leukemia ALL	blinatumomab Sensitive: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Melanoma Melanoma	Immunotherapy Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Gallbladder Cancer Gallbladder Cancer	palbociclib Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Glioma Glioma	vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Hepatocellular Cancer HCC	Immunotherapy Sensitive: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Melanoma Melanoma	palbociclib Sensitive: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Pancreatic Cancer Pancreatic Cancer	palbociclib Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Gastric Adenocarcinoma Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Prolymphocytic Leukemia Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies
CDKN2A deletion CDKN2A deletion	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + SNS-510 Sensitive: D – Preclinical
CDKN2A deletion CDKN2A deletion	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ribociclib + SNS-510 Sensitive: D – Preclinical
CDKN2A deletion CDKN2A deletion	Ewing Sarcoma Ewing Sarcoma	ASP7487 Sensitive: D – Preclinical
CDKN2A deletion CDKN2A deletion	Ewing Sarcoma Ewing Sarcoma	palbociclib Sensitive: D – Preclinical
CDKN2A deletion CDKN2A deletion	Renal Cell Carcinoma RCC	temsirolimus Sensitive: D – Preclinical